ICER will develop a report assessing the comparative clinical effectiveness and value of icosapent ethyl (Vascepa®, Amarin Pharma) and rivaroxaban (Xarelto®, Janssen Pharmaceuticals) as additive therapies for cardiovascular disease (CVD).
For questions, please contact Ellie Adair, Program Manager, at firstname.lastname@example.org.
University of Missouri-St. Louis
Century BC Room, Millennium Student Center
1 University Boulevard
St. Louis, MO 63121
The Midwest CEPAC will convene to deliberate and vote on evidence presented in ICER's report on additive CVD therapies.